ICUI

ICU MEDICAL INC/DE ICUI

NasdaqMid CapHealthcare

13F Pro quality score

Rank #1,733 of 2,925

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$551.68M

Quarter to Jun 30

Net income

$19.09M

Quarter to Jun 30

Free cash flow

$61.64M

Quarter to Jun 30

Operating margin

7.1%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$3.82B total
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ICUI

Earnings Per Share

13fpro.ai/company/ICUI

Loading ratio trend…

ICUI key financials by period

Reported revenue, net income and operating margin by fiscal year, from ICU MEDICAL INC/DE's annual filings on SEC EDGAR.

ICU MEDICAL INC/DE reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$2.2B$732.0K1.9%
FY 2024$2.4B$-117.7M1.8%
FY 2023$2.3B$-29.7M1.0%
FY 2022$2.3B$-74.3M-1.9%
FY 2021$1.3B$103.1M9.4%
FY 2020$1.3B$86.9M7.7%
Source: ICUI filings on SEC EDGAR →

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

ICUI insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

Congress trading in ICUI

7 transactions in ICUI reported by 3 members of Congress under the STOCK Act, most recent trade May 13, 2025. Reported transactions, not recommendations.

All Congress stock trades →

About ICU MEDICAL INC/DE (ICUI): stock profile, AI score and financials

ICU MEDICAL INC/DE (ICUI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ICUI at 48.6/100 on a composite quality score built from its SEC filings, placing it at rank #1,733 of 2,925 stocks — the bottom half of the AI-ranked universe. ICUI scores in the top quartile across earnings quality (97.6). Areas of concern include revenue growth (16.7) and balance sheet strength (39.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 35.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ICU MEDICAL INC/DE reports quarterly revenue of $551.7M, net income of $19.1M, an operating margin of 7.1%. Top institutional holders of ICUI by reported 13-F value include BlackRock, Jupiter Topco, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. ICUI trades on the Nasdaq exchange and files with the SEC under CIK 883984. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ICUI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ICU MEDICAL INC/DE directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 883984 →